Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — H1 2026 Earnings Presentation
13 slides from Tty Biopharm's earnings presentation, Sep 16, 2026
Slide 1: H1/2026 Operational Results Report
TTY Biopharm 4105 H1/2026 Operational Results Report Investor Relations Report 2026.09.16
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: H1/2026 Operational Highlights
Operational Results Report H1/2026 Operational Highlights 01 H1/2026 Operational Highlights H1/2026 Financial Performance Revenue Performance 2026 Outlook Key Product Achievements 2
Slide 4: Revenue Performance
Revenue Performance Operational Results Report Revenue, operating profit, and EPS of H1/2026 hit five-year highs. H1/2026 Operational 4 Highlights Unit：Million; dollar 3,172 Consolidated Revenue 2,971 YoY +6.8%、NT$3,172 million 3,000 2,648 3.4 H1/2026 2,428 Financial 2,203 2.7 3 Performance 2,000 Co
Slide 5: 2026 Key Product Achievements
2026 Key Product Achievements Operational Results Report Drug Ingredient: Aumolertinib Drug Classification: 3rd-Generation EGFR-TKI H1/2026 Oral Targeted Therapy Operational Highlights Manufacturing Site: TTY’s Lioudu Plant H1/2026 Financial 2026. 08 .01 Officially covered by National Health Insuran
Slide 6: 2026 Key Product Achievements
2026 Key Product Achievements Operational Results Report 01 First Domestically 03 Deepening Manufactured Drug Local Presence As Taiwan's first 3rd-generation EGFR-TKI oral • Establish an integrated production line to H1/2026 Operational targeted drug for lung cancer self-developed by a centralize ma
Slide 7: 2026 Key Product Achievements
2026 Key Product Achievements Operational Results Report September Delivery: On time with zero delays. October Vaccination Campaign: Launch of public/self-paid cell-based and adjuvanted flu vaccines. H1/2026 Operational Highlights H1/2026 Financial Performance Adjuvanted trivalent Cell-based flu vac
Slide 8: H1/2026 Financial Performance
Operational Results Report H1/2026 Operational Highlights H1/2026 Financial Performance 02 H1/2026 Financial Performance 2026 Outlook 7
Slide 9: H1/2026 Financial Performance
H1/2026 Financial Performance Operational Results Report Income Statement YoY YoY 2026 H1 2025 H1 (Unit: NT$ Thousands) Differences % Analysis Operating Revenue 3,172,151 2,970,900 201,251 6.8% • Operating revenue YoY +6.8% is due H1/2026 Operational Operating Cost 1,290,772 1,200,754 90,018 7.5% to
Slide 10: 2026 Outlook
Operational Results Report H1/2026 Operational Highlights H1/2026 Financial Performance 03 2026 Outlook 2026 Outlook 9
Slide 11: 2026 Outlook
2026 Outlook Operational Results Report Comprehensive Product Line Covering In-House R&D, In-Licensing, and International Collaborations Oncology 2025 2026 2027 2028 2029 H1/2026 XPOVIO Hematological Malignancies Operational (New Indication) Highlights T5260 Hematological Malignancies T5261 Breast C
Slide 12: Three Strategies Driving TTY's International Expansion
2026 Three Strategies Driving TTY’s International Expansion 營運成果報告 Global Submission Plan Lioudu Plant Equipment of Lipo-AB Investment in Lipo-AB Maintaining stable shipments to US. Adding a new lyophilization Export Obtaining drug approvals sequentially in Australia production line and planning to
Slide 13: Q&A
Q&A H1/2026 Operational Results Report TTY Biopharm 4105 Investor Relations Report 2026.09.16